# Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension

> **NCT00890591** · PHASE4 · COMPLETED · sponsor: **Daiichi Sankyo** · enrollment: 144 (actual)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary

## Key facts

- **NCT ID:** NCT00890591
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2007-06
- **Final completion:** 2007-08
- **Target enrollment:** 144 (ACTUAL)
- **Last updated:** 2009-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00890591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00890591, "Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00890591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*